Antibiotic Treatment for E. coli UTI with Specific Resistance Pattern

Treatment Algorithm and Rationale

• The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) recommends carbapenem-sparing approaches when possible, reserving meropenem for more resistant infections to prevent development of carbapenem resistance 1, 2
• Third-generation cephalosporins like ceftriaxone provide targeted coverage while preserving carbapenems (meropenem) for more resistant infections 1, 2
• European guidelines support BLBLI (beta-lactam/beta-lactamase inhibitor) use for pyelonephritis with moderate certainty of evidence 2

Duration of Therapy and Follow-up

• For complicated UTI or pyelonephritis, 10-14 days of therapy is recommended 4
• Consider transition to oral therapy (based on susceptibility) once clinical improvement is observed 2
• Clinical response should be evident within 48-72 hours of appropriate therapy, and if symptoms persist, obtain repeat urine culture to guide targeted therapy 3